Does IHU-Méditerranée Infection influence Gilead Sciences' stock price?
E. Chabrière
New Microbes and New Infections · 2021
doi:10.1016/j.nmni.2020.100711 (opens in a new tab)
We email you when a new notice or a question about this paper appears.
Abstract
During COVID-19 pandemic the Gilead Sciences stock prices rose sharply with large variations. These fluctuations have been tentatively related to communications, publications or leaks about remdesivir or hydroxychloroquine/azithromycin treatment.
Abstract licence: CC BY-NC
Reads
Read by people on this page
None yet.
Checked or read by AI through naulon
None yet.
A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.
Are you an author?
Is this your paper?
Claim it to add your note and be paid when agents cite it. Free.